Active surveillance is the preferred approach to clinical stage I testicular cancer.
暂无分享,去创建一个
T. Powles | P. Albers | C. Bokemeyer | P. Warde | S. Tyldesley | L. Einhorn | S. Daneshmand | S. Olgac | P. Grimison | M. Jewett | C. Beard | C. Kollmannsberger | R. Cathomas | C. Sweeney | K. Fizazi | C. Porter | B. Roth | B. Hayes-Lattin | A. So | R. Foster | Craig R. Nichols | G. Toner | Semra Olgac
[1] Barriers to the implementation of surveillance for stage I testicular seminoma. , 2012, International journal of radiation oncology, biology, physics.
[2] J. Patard,et al. Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Duncan,et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] G. Rustin,et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] O. Ståhl,et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Huddart,et al. Canadian consensus guidelines for the management of testicular germ cell cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[7] F. Mayer,et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. , 2010, Swiss medical weekly.
[8] M. Gleave,et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Horwich,et al. Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. , 2010 .
[10] S. Culine,et al. Management of testicular neoplasms in France and compliance with national guidelines. , 2010 .
[11] P. Warde,et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. , 2010 .
[12] L. Schwartz,et al. NCCN clinical practice guidelines in oncology: testicular cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] R. Bremnes,et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Fosså,et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. , 2008, European urology.
[15] P. Warde,et al. A comprehensive systematic review of testicular germ cell tumor surveillance. , 2007, Critical reviews in oncology/hematology.
[16] M. Louwman,et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Pond,et al. Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT) , 2007 .
[18] R. Huddart,et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Carles,et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Horwich,et al. Guidelines on testicular cancer. , 2005, European urology.
[21] T. Powles,et al. The changing presentation of germ cell tumours of the testis between 1983 and 2002 , 2005, BJU international.
[22] M. Kattan,et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Trump. Mortality after cure of testicular seminoma. Zagars GK, Ballo MT, Lee AK, Strom SS, Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.: J Clin Oncol 2004;22:640–7 , 2004 .
[24] Andrew K. Lee,et al. Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Horwich,et al. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis , 2002 .
[26] P. Hall,et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.
[27] P. Goodman,et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.